開發(fā)新的抗癌藥物是癌癥研究中變化最快的方面之一。研究中的新藥為快速傳播新的抗癌藥物信息提供了一個平臺。發(fā)表的論文引起了醫(yī)學(xué)化學(xué)家、毒理學(xué)家、藥理學(xué)家、生物統(tǒng)計(jì)學(xué)家和臨床腫瘤學(xué)家的興趣。正在研究的新藥為整個開發(fā)抗癌藥物的科學(xué)家群體提供了最快的可能發(fā)表新發(fā)現(xiàn)和結(jié)果的途徑。每一期都有關(guān)于抗癌藥物開發(fā)的原創(chuàng)文章。其他部分是專門用于邀請?jiān)u論文章和信件的編輯。該雜志還提供了出版專門用于開發(fā)新的抗癌藥物的專題討論會和專題討論會的會議記錄的機(jī)會。如果他們增加了對研究藥物的理解，該雜志并不反對發(fā)表負(fù)面結(jié)果的臨床試驗(yàn)。正在研究的新藥跨越了所有通常的路線或子學(xué)科，為相關(guān)調(diào)查和討論適合于整個抗癌新藥開發(fā)領(lǐng)域的關(guān)鍵問題提供了一個場所。

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist toxicologist pharmacist pharmacologist biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents. Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents the journal is not adverse to publishing clinical trials with negative results. Investigational New Drugs cuts across all the usual lines or subdisciplines providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.